GSK and WebMD join on headache education
PARSIPPANY, N.J. – To kick-off National Headache Month, GlaxoSmithKline and WebMD launched web tools aimed at educating headache sufferers on the condition and, more importantly, how to manage head pain, with new tools and engaging content.
"Here's a situation where the whole is greater than the sum of its parts. By coupling the headache expertise that the makers of Excedrin offer with the timely and trusted health information provided by WebMD, we now have an even more robust offering for headache sufferers everywhere," said Jason Milligan, senior brand manager, Excedrin.
"Millions of consumers turn to WebMD each month to find information about managing headaches and migraines," said Michael Smith, chief medical editor, WebMD. "Both WebMD and the makers of Excedrin have a shared goal of helping consumers to better understand their headache symptoms so they can make more informed decisions about treatment options."
An element of the collaboration includes a survey conducted by WebMD, which shows significant differences between what headache sufferers are doing to treat their pain and what doctors recommend. Findings from the new WebMD survey show that one out of three respondents reports suffering from headaches weekly. According to the survey, 46% of respondents choose to "tough out" their headaches, despite doctor advice. In fact, nine out of 10 physicians suggest not toughing out headaches and eight out of 10 suggest treating headaches early, because there is support for the idea that medications work better when taken at the first sign of a headache.
In addition to key insights from the survey, the following resources are now available:
- To help headache and migraine sufferers easily understand which Excedrin product is right for them, the makers of Excedrin developed a Product Selector Tool, available on Excedrin.com. The tool includes a short quiz to help identify the user's symptoms and provides a product recommendation that best suits their needs;
- Consumers and healthcare professionals will also have access to headache-related content and tools developed by WebMD's editorial team on WebMD.com/headaches and Medscape.com. These destinations will feature news and articles related to mild to moderate, tension, cluster and migraine headaches and slideshows that depict surprising headache triggers; and
- Consumers can access the WebMD Headache Assessments tool, which helps consumer analyze headaches they may experience, and the WebMD Headache Map, which provides content related to possible headache types based on the headache location and frequency.
Thync launches neurosignaling device to either energize or induce calm
LOS GATOS, Calif. — Thync has launched a consumer wearable designed to either energize the user or make them calmer. The neurosignaling device is operated with an accompanying app to deliver Thync Vibes, the company stated.
"Our mission at Thync is to ‘unlimit’ people. Thync brings together innovations in neuroscience and engineering so you can access your own abilities," said Isy Goldwasser, CEO Thync. “Our product will help many people improve and enjoy their life more.”
Based upon research from neuroscientists and engineers from Harvard, MIT, Stanford and Arizona State University, Thync's proprietary technology relies on low levels of pulsed electrical energy to signal specific neural pathways, allowing users to dial up or dial down their stress responses and energy levels.
“Today's fast-paced life requires us to switch situations and change mindsets at increasing speed. Thync helps people find calm and focus throughout your day,” said Jamie Tyler, chief science officer. “Thync is the result of groundbreaking research at some of the best academic institutions, combined with cutting-edge engineering that leverages patented algorithms. This has culminated in today's launch of a device that, for the first time, lets you safely tap into the power of your own mind.”
Based on its intended use in lifestyle applications, the Food and Drug Administration exempted the Thync System from medical device regulations requiring pre-market notification or approval, Thync stated.
Thync can be purchased at www.Thync.com for $299.
GoJo makes commitment to antibiotic stewardship
AKRON, Ohio — GoJo pledged its commitment to antibiotic stewardship at the White House Forum on Tuesday. GoJo was among 150 companies at the White House Forum to announce commitments over the next five years to slow the emergence of antibiotic-resistant bacteria, detect resistant strains, preserve the efficacy of existing antibiotics and prevent the spread of resistant infections.
“A primary prevention approach to reduce the need for antibiotics is effective hand hygiene,” Joe Kanfer, chairman and CEO of GoJo, who is attending the Forum, said. “As we know, hand hygiene is one of the best measures you can take to prevent the spread of illness-causing germs. Staying healthy and preventing infections from happening is a very effective way to reduce the use of antibiotics. This is why practicing good hand hygiene — handwashing and hand sanitizing — is so important to overcoming the challenge of antibiotic resistance. We look forward to working with other organizations that share this dedication to improving public health.”
Last year, President Barack Obama signed an Executive Order launching Federal efforts to combat the rise in antibiotic-resistant bacteria. The Administration also issued its National Strategy on Combating Antibiotic-Resistant Bacteria, which outlines steps the U.S. government will take to improve prevention, detection and control of resistant pathogens. Earlier this year, the White House released its National Action Plan to Combat Antibiotic-Resistant Bacteria, an effort that identifies critical actions to be taken by government over the next five years. In addition, the President's FY 2016 Budget proposed nearly doubling the amount of Federal funding for combating and preventing antibiotic resistance to more than $1.2 billion.
Loading Post Please Wait...